500 patients67,039 observations150 daysLIVE

Patient P-03221

Synthetic patientONX-7 · Day 112 · 55–64 · F · baseline S06Open companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
53%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S06
  2. Day 50 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 102 GI-04 recommendedGI Support Protocol GI-04
  4. Day 103 Patient acceptedStarted GI-04 in the companion
  5. Day 111 No meaningful changeGI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days
  • GI instability+12
  • Toxicity+10
  • Treatment adherence-7
  • Inflammatory activity+5
  • Nutritional resilience-5

What helped?

  • GI Support Protocol GI-04Day 102
    Result: no meaningful change
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
60%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 77% showed improvement
  • median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 39/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 46
  • Autonomic recovery 45
    • WearableResting HR 79 bpm
    • WearableShort sleep window
  • Mucosal barrier integrity 30
    • Daily logGI symptom score 49 and rising
    • WearableSleep 5.2 h, below personal baseline
DNA
Fictional pharmacogenomic panel
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.7 · butyrate capacity 39/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
51 ms
Sleep
5.5 h
Steps
5,438
Resting HR
76 bpm
Daily log: GI score 49, nutritional resilience 43, adherence 88.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0329249%S1462
P-0334648%S17GI-04improved71
P-0312046%S1461
P-0337845%S1059
P-0340545%S1662
P-0316043%S1863
P-0302742%S2062
P-0337942%S12GI-04improved51
P-0320740%S0461
P-0321839%S2056
P-0307438%S0160
P-0328738%S1755